Topics
Glioblastoma | Diagnosis | Magnetic resonance imaging | Differentiation
Home > Publications > Topics > Glioblastoma > Diagnosis > Magnetic resonance imaging > Differentiation
Differentiation between glioblastoma, primary CNS lymphoma and metastasis
Chuthip
P, Sitthinamsuwan B, Witthiwej T, Tansirisithikul C, Khumpalikit
I, Nunta-Aree S.
Predictors
for the Differentiation between Glioblastoma, Primary Central
Nervous System Lymphoma, and Metastasis in Patients with a
Solitary Enhancing Intracranial Mass.
Asian
J Neurosurg.
2024 Jun 6;19(2):186-201. doi:
10.1055/s-0044-1787051. PMID:
38974428. Observational study. ˍ
Differentiation between glioblastoma and primary CNS lymphoma
Zhang Y, Luo X, Zhu Y, Zhang Q, Liu B.
Differentiation
between primary central nervous system lymphomas and gliomas
according to pharmacokinetic parameters derived from dynamic
contrast-enhanced magnetic resonance imaging.
Heliyon.
2024 Jun 6;10(12):e32619. doi:
10.1016/j.heliyon.2024.e32619. PMID:
38952379.
Observational study. ˍ
Differentiation between glioblastoma and primary CNS lymphoma
Würtemberger
U, Diebold M, Rau A, Akgün V, Becker L, Beck J, Reinacher PC,
Taschner CA, Reisert M, Fehrenbacher L, Erny D, Scherer F,
Hohenhaus M, Urbach H, Demerath T.
Advanced
diffusion imaging reveals microstructural characteristics of
primary CNS lymphoma, allowing differentiation from glioblastoma.
Neurooncol
Adv.
2024 Jun 8;6(1):vdae093. doi:
10.1093/noajnl/vdae093. PMID:
38946879. Observational study. ˍ
Differentiating Bevacizumab-Related Cytotoxicity from Tumor Recurrence and Radiation Necrosis
Khalaj K, Jacobs MA, Zhu JJ, Esquenazi Y, Hsu S, Tandon N,
Akhbardeh A, Zhang X, Riascos R, Kamali A.
The
Use of Apparent Diffusion Coefficient Values for Differentiating
Bevacizumab-Related Cytotoxicity from Tumor Recurrence and
Radiation Necrosis in Glioblastoma.
Cancers
(Basel). 2024 Jul 2;16(13):2440. doi:
10.3390/cancers16132440. PMID:
39001500.
Observational study. ˍ
Differentiation between progression and pseudoprogression
van
Dorth D, Croese RJI, Jiang FY, Schmitz-Abecassis B, Taphoorn MJB,
Smits M, Dirven L, van Osch MJP, de Bresser J, Koekkoek JAF.
Perfusion
MRI-based differentiation between early tumor progression and
pseudoprogression in glioblastoma and its use in clinical
practice.
Neurooncol
Pract.
2024 Oct 15;12(2):281-290. doi:
10.1093/nop/npae099. PMID:
40110054. Observational study. ˍ
Differentiation between glioblastoma and primary CNS lymphoma
Chen Z, Liu H, Yang A, Liao J, Wu Z, Chen J, Miao W.
68Ga-Pentixafor PET in Combination
With MRI Improves the Differential Diagnosis of Glioblastoma and
Primary Central Nervous System Lymphoma.
Clin
Nucl Med. 2025 Jan 6. doi:
10.1097/RLU.0000000000005657. PMID:
39761437. Observational study˰
ˍ
Differentiation between infiltrating tumor and edema
Kuroda H, Okita Y, Arisawa A, Utsugi R, Murakami K, Hirayama R,
Kijima N, Arita H, Kinoshita M, Fujimoto Y, Nakamura H, Kagawa N,
Tomiyama N, Kishima H.
Cerebral blood
flow and histological analysis for the accurate differentiation of
infiltrating tumor and vasogenic edema in glioblastoma.
PLoS
One. 2025 Jan 10;20(1):e0316168. doi:
10.1371/journal.pone.0316168. PMID:
39792964. Observational study. ˍ
Differentiating radiation necrosis from tumor recurrence
Lv XQ, Shen WR, Guo Z, Xie XD.
Diagnostic
value and efficacy of multimodal magnetic resonance imaging in
differentiating radiation necrosis from tumor recurrence in
glioblastomas.
Acta
Radiol. 2025 Feb 4:2841851241310392. doi:
10.1177/02841851241310392. PMID:
39905844. Observational study˰
ˍ
Differentiating glioblastomas from adult diffuse gliomas
Zhang HW, Deng HZ, Feng YN, Tang XM, Su RR, Ouyang Y, Lin F, Wang
YL, Lei Y, Huang B.
Evaluating the
efficacy of advanced imaging techniques in differentiating
histological and molecular glioblastomas from adult diffuse
gliomas: PWI, DWI, and MRS.
Acta
Radiol. 2025 May 1:2841851251333328. doi:
10.1177/02841851251333328. PMID:
40313055.
Observational study˰
ˍ